"In response to the need for mRNA COVID-19 vaccines during the pandemic ... and end-to-end RNA expertise under one roof, ...

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) on November 6 and set a ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

In a related JAMA Viewpoint, the authors noted that COVID-19 peaked in 2020 and 2021 as the third highest cause of mortality ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Crispr Therapeutics recently received FDA and EMA approval for Casgevy. Read why CRSP stock is compelling investment in the ...

An abundance of evidence indicates the mRNA COVID-19 vaccines are remarkably safe and work well to protect against severe ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

About Checkpoint Therapeutics Checkpoint Therapeutics ... including the risk that the evolving and unpredictable Russia/Ukraine conflict and COVID-19 pandemic delay achievement of those milestones.

The study was conducted between 2021 and 2023, during the height of the COVID-19 global pandemic ... Prevention during the ...

A critical challenge during the early COVID-19 pandemic was determining whether a patient would survive the infection or die ...